parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in microglia (528 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 15447

RAPGEF6 in dopamine neurons, braak+0.29 (p 0.443) → +0.11 (p 0.773)receipt 15455
RAPGEF6 in microglia, braak+0.02 (p 0.963) → +0.17 (p 0.663)receipt 15454

receipt 15455: RAPGEF6 in dopamine neurons, braak

power: full sample +0.23 (p 0.369, n 18), 95% CI -0.27 to +0.63. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.31 (p 0.218, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.277, n 18). could be the mix.
skeptic: leave-one-out range +0.13 to +0.37, sign flips 0; without severely affected donors +0.23 (p 0.369, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RAPGEF6 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15454: RAPGEF6 in microglia, braak

power: full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.908, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.09 (p 0.735, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.16, sign flips 7; without severely affected donors +0.01 (p 0.969, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RAPGEF6 in microglia.

case closed: nothing better to follow up.

loading the receipts